ZA202408076B - Aza-tetracyclic oxazepine compounds and uses thereof - Google Patents
Aza-tetracyclic oxazepine compounds and uses thereofInfo
- Publication number
- ZA202408076B ZA202408076B ZA2024/08076A ZA202408076A ZA202408076B ZA 202408076 B ZA202408076 B ZA 202408076B ZA 2024/08076 A ZA2024/08076 A ZA 2024/08076A ZA 202408076 A ZA202408076 A ZA 202408076A ZA 202408076 B ZA202408076 B ZA 202408076B
- Authority
- ZA
- South Africa
- Prior art keywords
- tetracyclic
- aza
- oxazepine compounds
- compounds
- oxazepine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263343959P | 2022-05-19 | 2022-05-19 | |
| PCT/US2023/022914 WO2023225302A1 (en) | 2022-05-19 | 2023-05-19 | Aza-tetracyclic oxazepine compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202408076B true ZA202408076B (en) | 2026-01-28 |
Family
ID=86895902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2024/08076A ZA202408076B (en) | 2022-05-19 | 2024-10-25 | Aza-tetracyclic oxazepine compounds and uses thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20240025919A1 (enExample) |
| EP (1) | EP4526309A1 (enExample) |
| JP (2) | JP7735594B2 (enExample) |
| KR (1) | KR20250013185A (enExample) |
| CN (1) | CN119365467A (enExample) |
| AR (1) | AR129388A1 (enExample) |
| AU (1) | AU2023272945A1 (enExample) |
| CA (1) | CA3257445A1 (enExample) |
| CL (1) | CL2024003491A1 (enExample) |
| CO (1) | CO2024017330A2 (enExample) |
| CR (1) | CR20240508A (enExample) |
| IL (1) | IL316696A (enExample) |
| MX (1) | MX2024014176A (enExample) |
| PE (1) | PE20250752A1 (enExample) |
| TW (1) | TW202400170A (enExample) |
| WO (1) | WO2023225302A1 (enExample) |
| ZA (1) | ZA202408076B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119569702A (zh) | 2018-04-04 | 2025-03-07 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| CA3220929A1 (en) * | 2021-06-21 | 2022-12-29 | Xin Li | Fused tetracyclic compound, preparation method therefor and application thereof in medicine |
| KR20240029051A (ko) * | 2021-07-02 | 2024-03-05 | 상하이 드 노보 파마테크 컴퍼니 리미티드 | Kras g12d 억제제 및 이의 용도 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| CR20240508A (es) | 2022-05-19 | 2024-12-20 | Genentech Inc | Compuestos aza-tetracíclicos de oxazepina y usos de los mismos |
| TW202409051A (zh) * | 2022-07-27 | 2024-03-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠環類化合物、其製備方法及其在醫藥上的應用 |
| KR20250060956A (ko) | 2022-08-05 | 2025-05-07 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| WO2024243186A2 (en) * | 2023-05-22 | 2024-11-28 | Board Of Regents, The University Of Texas System | Heterocyclic compounds as nras inhibitors |
| TW202504599A (zh) | 2023-06-30 | 2025-02-01 | 美商必治妥美雅史谷比公司 | Kras抑制劑 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024333376A1 (en) * | 2023-08-31 | 2026-02-12 | Suzhou Zanrong Pharma Limited | Kras inhibitors and uses thereof |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| TW202540122A (zh) * | 2023-11-22 | 2025-10-16 | 美商建南德克公司 | Ｋｒａｓ－ｇ１２ｄ之氮雜－四環氧氮呯抑制劑的多晶型物及合成方法 |
| WO2025123007A1 (en) * | 2023-12-08 | 2025-06-12 | Kestrel Therapeutics Inc. | Ras inhibitors and methods of use thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202600562A (zh) | 2024-03-15 | 2026-01-01 | 美商建南德克公司 | 線性取代之氧氮呯－５－酮ｋｒａｓ－ｇ１２ｄ抑制劑 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026011344A1 (en) * | 2024-07-10 | 2026-01-15 | Nikang Therapeutics, Inc. | Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026073024A1 (en) * | 2024-09-30 | 2026-04-02 | Gilead Sciences, Inc. | Kras g12d inhibitors for the treatment of cancer |
| WO2026080548A1 (en) | 2024-10-10 | 2026-04-16 | Genentech, Inc. | Method of treating cancer using the kras g12d inhibitor gcd-7035 |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| CN121108144A (zh) * | 2025-09-02 | 2025-12-12 | 领泰生物医药(绍兴)有限公司 | 一种含氮杂多环化合物的制备方法及其中间体 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| AR111776A1 (es) * | 2017-05-11 | 2019-08-21 | Astrazeneca Ab | Heteroarilos inhibidores de las proteínas ras mutantes de g12c |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| ES3004042T3 (en) | 2018-11-09 | 2025-03-11 | Hoffmann La Roche | Fused ring compounds |
| CA3148745A1 (en) * | 2019-08-29 | 2021-03-04 | Xiaolun Wang | Kras g12d inhibitors |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| US20230174518A1 (en) | 2020-04-24 | 2023-06-08 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| CN116867792A (zh) | 2021-02-09 | 2023-10-10 | 基因泰克公司 | 四环氧氮杂䓬化合物及其用途 |
| WO2022188729A1 (en) | 2021-03-07 | 2022-09-15 | Jacobio Pharmaceuticals Co., Ltd. | Fused ring derivatives useful as kras g12d inhibitors |
| JP2024510022A (ja) | 2021-03-17 | 2024-03-05 | ▲勁▼方医▲薬▼科技（上海）有限公司 | ピリミジン縮合環系化合物、その製造方法、及び使用 |
| WO2022199587A1 (zh) * | 2021-03-24 | 2022-09-29 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
| WO2022206723A1 (zh) | 2021-03-30 | 2022-10-06 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| CA3220929A1 (en) * | 2021-06-21 | 2022-12-29 | Xin Li | Fused tetracyclic compound, preparation method therefor and application thereof in medicine |
| KR20240029051A (ko) | 2021-07-02 | 2024-03-05 | 상하이 드 노보 파마테크 컴퍼니 리미티드 | Kras g12d 억제제 및 이의 용도 |
| CN117677624A (zh) | 2021-07-19 | 2024-03-08 | 上海艾力斯医药科技股份有限公司 | 新型吡啶并嘧啶衍生物 |
| EP4373827A4 (en) * | 2021-07-23 | 2025-06-04 | Suzhou Zanrong Pharma Limited | KRAS G12D inhibitors and uses thereof |
| JP2024532735A (ja) | 2021-08-10 | 2024-09-10 | アムジエン・インコーポレーテツド | 複素環式化合物及び使用方法 |
| TW202330529A (zh) | 2021-08-10 | 2023-08-01 | 美商安進公司 | 雜環化合物及使用方法 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| CN117794930A (zh) | 2021-09-03 | 2024-03-29 | 苏州亚盛药业有限公司 | Kras抑制剂 |
| EP4408851A4 (en) | 2021-09-27 | 2025-09-17 | Jacobio Pharmaceuticals Co Ltd | POLYCYCLIC FUSED RING DERIVATIVES AND THEIR USE |
| CN116199703A (zh) | 2021-12-01 | 2023-06-02 | 江苏恒瑞医药股份有限公司 | 稠合四环杂环化合物、其制备方法及其在医药上的应用 |
| WO2023103906A1 (zh) | 2021-12-07 | 2023-06-15 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| CN116332948A (zh) | 2021-12-22 | 2023-06-27 | 翰森生物有限责任公司 | 一种含氮四环化合物及其制备方法和药用用途 |
| EP4471037A1 (en) | 2022-01-30 | 2024-12-04 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinoline compound and use thereof |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| CA3247639A1 (en) | 2022-05-06 | 2023-11-09 | PAQ Therapeutics Inc. | CHIMERAS TARGET KRAS-G12D PROTEOLYSIS |
| CR20240508A (es) | 2022-05-19 | 2024-12-20 | Genentech Inc | Compuestos aza-tetracíclicos de oxazepina y usos de los mismos |
| TW202409051A (zh) | 2022-07-27 | 2024-03-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠環類化合物、其製備方法及其在醫藥上的應用 |
| CN117462688A (zh) | 2022-07-28 | 2024-01-30 | 江苏恒瑞医药股份有限公司 | 一种包含kras g12d抑制剂的组合物 |
| CN119384279A (zh) | 2022-07-29 | 2025-01-28 | 江苏恒瑞医药股份有限公司 | 一种包含kras g12d抑制剂的药物组合物 |
| CN119698418A (zh) | 2022-08-11 | 2025-03-25 | 百济神州(苏州)生物科技有限公司 | 杂环化合物、其组合物及用其进行治疗的方法 |
| WO2024041573A1 (en) | 2022-08-25 | 2024-02-29 | Zai Lab (Shanghai) Co., Ltd. | Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof |
| CN117771378A (zh) | 2022-09-29 | 2024-03-29 | 贝达药业股份有限公司 | 提高kras抑制剂生物利用度的药物组合及其应用 |
| CN119947725A (zh) | 2022-09-30 | 2025-05-06 | 应世生物科技(南京)有限公司 | Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途 |
| TW202430182A (zh) | 2022-12-14 | 2024-08-01 | 大陸商上海科州藥物研發有限公司 | 作為ｋｒａｓ抑制劑的雜環化合物，及其製備和治療用途 |
| CN118221699A (zh) | 2022-12-20 | 2024-06-21 | 江苏恒瑞医药股份有限公司 | 一种kras g12d抑制剂的可药用盐、晶型及其制备方法 |
| JP2026500533A (ja) | 2022-12-20 | 2026-01-07 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | Ｋｒａｓ ｇ１２ｄ阻害剤の結晶形及び調製方法 |
-
2023
- 2023-05-19 CR CR20240508A patent/CR20240508A/es unknown
- 2023-05-19 KR KR1020247041569A patent/KR20250013185A/ko active Pending
- 2023-05-19 EP EP23732731.7A patent/EP4526309A1/en active Pending
- 2023-05-19 TW TW112118800A patent/TW202400170A/zh unknown
- 2023-05-19 PE PE2024002607A patent/PE20250752A1/es unknown
- 2023-05-19 WO PCT/US2023/022914 patent/WO2023225302A1/en not_active Ceased
- 2023-05-19 CN CN202380041256.4A patent/CN119365467A/zh active Pending
- 2023-05-19 AR ARP230101266A patent/AR129388A1/es unknown
- 2023-05-19 AU AU2023272945A patent/AU2023272945A1/en active Pending
- 2023-05-19 JP JP2024568561A patent/JP7735594B2/ja active Active
- 2023-05-19 US US18/199,449 patent/US20240025919A1/en not_active Abandoned
- 2023-05-19 IL IL316696A patent/IL316696A/en unknown
- 2023-05-19 CA CA3257445A patent/CA3257445A1/en active Pending
-
2024
- 2024-05-28 US US18/676,200 patent/US12338256B2/en active Active
- 2024-10-25 ZA ZA2024/08076A patent/ZA202408076B/en unknown
- 2024-11-14 CL CL2024003491A patent/CL2024003491A1/es unknown
- 2024-11-15 MX MX2024014176A patent/MX2024014176A/es unknown
- 2024-12-17 CO CONC2024/0017330A patent/CO2024017330A2/es unknown
-
2025
- 2025-04-25 US US19/190,368 patent/US20260062425A1/en active Pending
- 2025-08-26 JP JP2025140269A patent/JP2026000916A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240368186A1 (en) | 2024-11-07 |
| KR20250013185A (ko) | 2025-01-31 |
| WO2023225302A1 (en) | 2023-11-23 |
| US12338256B2 (en) | 2025-06-24 |
| CR20240508A (es) | 2024-12-20 |
| PE20250752A1 (es) | 2025-03-13 |
| JP7735594B2 (ja) | 2025-09-08 |
| CO2024017330A2 (es) | 2024-12-30 |
| US20240025919A1 (en) | 2024-01-25 |
| CL2024003491A1 (es) | 2025-04-11 |
| EP4526309A1 (en) | 2025-03-26 |
| AU2023272945A1 (en) | 2024-11-07 |
| MX2024014176A (es) | 2024-12-06 |
| IL316696A (en) | 2024-12-01 |
| JP2025517395A (ja) | 2025-06-05 |
| US20260062425A1 (en) | 2026-03-05 |
| TW202400170A (zh) | 2024-01-01 |
| JP2026000916A (ja) | 2026-01-06 |
| AR129388A1 (es) | 2024-08-21 |
| CA3257445A1 (en) | 2023-11-23 |
| CN119365467A (zh) | 2025-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023009135A (es) | Compuestos de oxazepina tetraciclica y usos de estos. | |
| CR20240508A (es) | Compuestos aza-tetracíclicos de oxazepina y usos de los mismos | |
| MX2023011873A (es) | Compuestos de oxazepina y sus usos en el tratamiento del cancer. | |
| MY205856A (en) | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | |
| MX2025001810A (es) | Compuestos que participan en la union cooperativa y usos de los mismos | |
| WO2022031952A3 (en) | Treatments for cancers having kras mutations | |
| MX2025008674A (es) | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos | |
| MX2022012621A (es) | Enlazadores de variantes de carga. | |
| MX2019010804A (es) | Compuestos de benzazepina, conjugados y usos de los mismos. | |
| FR3107648B1 (fr) | conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie | |
| CY1107778T1 (el) | Ανθρωπινα cd45+ ή/και ινοβλαστης + μεσεγχυματικα βλαστικα κυτταρα | |
| MX2022010466A (es) | Tratamiento conjunto contra tipos de cancer hematologico. | |
| GEP20227458B (en) | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases | |
| WO2024249769A8 (en) | Combination therapy for treating hematological cancers | |
| WO2022197930A3 (en) | Panels and methods for treatment of diffuse large b-cell lymphoma | |
| PH12022553333A1 (en) | Markers for use in methods for treating cancers with antibody drug conjugates (adc) | |
| MX2023015286A (es) | Conjugado ligando-farmaco y uso de este. | |
| PH12022551008A1 (en) | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma | |
| MX2024013869A (es) | Conjugados anticuerpo-farmaco 5t4 y usos de los mismos | |
| NO20053947L (no) | Forbedrede antitumorale behandlinger. | |
| FR2945210B1 (fr) | Combinaison antitumorale comprenant l'ave8062 et le sorafenib | |
| WO2020072519A8 (en) | Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy | |
| MX2023008485A (es) | Anticuerpos inmunomoduladores y usos de estos. | |
| ZA202106807B (en) | Antibodies having specificity for btn2 and uses thereof | |
| MX2024005589A (es) | Combinaciones de lurbinectedina y atezolizumab. |